Level B· Emerging clinical evidence with positive signalsRandomized Controlled TrialPubMedOpen access

Novel Utilization of the Regenerative Peripheral Nerve Interface Technique after Unsuccessful Nerve Release for Bilateral Frontal Migraines.

Toliver B., Egan B., Sparks P., Morris A., Hadad I.

Randomized Controlled Trial on Face & Skin, published in Plast Reconstr Surg Glob Open (2024) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Randomized Controlled Trial
Journal
Plast Reconstr Surg Glob Open (2024)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
38689942
PMCID
PMC11057810
DOI
10.1097/GOX.0000000000005769

Abstract (original English)

Regenerative peripheral nerve interface (RPNI) is a surgical technique whose indications include preventing or treating painful neuromas after amputation or peripheral nerve injuries. The procedure involves implanting the distal end of a transected peripheral nerve containing sensory fibers into a selected free muscle graft. Although RPNI procedures have primarily been used after limb amputations, select case reports detail the potential for RPNI to mitigate other sources of neuropathic pain, introducing novel uses to its clinical utility. We present the case of a 49-year-old woman who presented to our clinic in June 2021 with chronic frontal migraines with right retro-orbital pain. Bilateral supraorbital and supratrochlear nerve releases with fat grafting were performed in August 2018 via a blepharoplasty approach; however, this procedure was unsuccessful in reducing her neuropathic pain. After discussion with the patient, we elected to proceed with transection of bilateral supraorbital and supratrochlear nerves with RPNI. The postoperative course was uneventful. Follow-up visits up to 1-year postoperative revealed that she had adequate pain control, discontinued her migraine medications, and reported satisfaction with the procedure. The novel RPNI surgical technique may be a low-risk adjunctive option in the surgical management of refractory supraorbital and supratrochlear ne

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research